Patent attorney Dr. Ulrike Herr joins Maiwald as partner on 1 February 2022. Formerly with the Munich office of Isenbruck Bösl Hörschler, where she became a partner in 2014, Dr. Herr practices in the areas of polymer chemistry, pharmaceuticals and medical technology, among others.
Dr. Herr has more than 20 years of experience in intellectual property protection. After working for several years as a patent and licensing manager in the plant protection segment of Bayer AG and Bayer CropScience AG, in 2004 she took up a position in one of Munich’s leading patent attorney firms before moving to Isenbruck Bösl Hörschler in 2010.
Dr. Herr’s activities includes drafting and filing patent applications, coordinating patent prosecutions worldwide, representing clients in opposition and appeal proceedings before the European Patent Office (EPO), as well as in nullity proceedings before the German Federal Patent Court (BPatG) and Federal Supreme Court (BGH). In addition to preparing freedom-to-operate and validity opinions and advising on long term strategic planning, Dr. Herr further specialises in supplementary protection certificates (SPCs) for medicinal and plant protection products. She coordinates SPC filings across Europe and has wide experience in SPC invalidity proceedings. Acting on behalf of a client, she played a leading role in the nullity proceedings against Gilead’s SPC for the HIV drug Truvada® (BGH X ZR 172/18).
Dr. Herr’s practical patent experience covers a wide range of technical fields. These include pharmaceuticals (active ingredients, new medical indications, formulations and manufacturing processes), dental materials and dental implants, chemistry (organic chemistry, fibers and polymers in particular), food chemistry (sweeteners and sweetening enhancers) and medical devices.
Dr. Derk Vos, a partner with Maiwald: “We are very pleased to have such a highly qualified and skilled patent attorney as Dr. Ulrike Herr in our life science team. With her experience and competence in the field of chemistry and pharmaceuticals and especially supplementary protection certificates, she is a great asset for our team. We wish Ulrike every success in her new role at Maiwald and look forward to working with her.”